Adenosine Methylation Level of miR-125a-5p Promotes Anti-PD-1 Therapy Escape through the Regulation of IGSF11/VSIG3 Expression.
Gwenola Bougras-CartronArulraj NadaradjaneMarie-Pierre JoallandLisenn Lalier-BretaudeauJudith RaimbourgPierre-François CartronPublished in: Cancers (2023)
Our data provide a biomarker (m6A-miR-125a-5p level) and two therapeutic solutions (anti-IGSF11 antibody and METTL3 inhibitor) that could potentially address the anti-PD1 therapy failure in the context of precision and personalized medicine.